Mouse HMGB-1(Highmobility group protein B1) ELISA Kit
中文名称:小鼠高迁移率族蛋白B1(HMGB-1)酶联免疫吸附测定试剂盒
别称:
HMGB1、HMG1、HMG3、SBP-1、Amphoterin
Price:
Size:
96T
48T
96T*5
- 反应性: Mouse
- 检测范围: 15.63-1000 pg/mL
- 灵敏度: 9.38 pg/mL
产品应用 | ELISA |
检测原理 | 本试剂盒采用双抗体夹心ELISA法。用抗小鼠HMGB-1抗体包被于酶标板上,实验时样品(或标准品)中的小鼠HMGB-1会与包被抗体结合。后依次加入生物素化的抗小鼠HMGB-1抗体和辣根过氧化物酶标记的亲和素,抗小鼠HMGB-1抗体与结合在包被抗体上的小鼠HMGB-1结合,生物素与亲和素特异性结合而形成免疫复合物,游离的成分被洗去。加入显色底物(TMB),TMB在辣根过氧化物酶的催化下呈现蓝色,加终止液后变成黄色。用酶标仪在450 nm波长处测OD值,HMGB-1浓度与OD450值之间呈正比,通过绘制标准曲线计算出样品中HMGB-1的浓度。 |
反应类型 | Sandwich-ELISA |
规格 |
96T
/ 48T
/ 96T*5
|
反应时间 | 3.5h |
反应性 | Mouse |
检测方法 | Colormetric |
检测范围 | 15.63-1000 pg/mL |
灵敏度 | 9.38 pg/mL |
样本体积 | 100μL |
样本类型 | 血清、血浆或其他生物体液 |
特异性 | 可检测样本中的小鼠HMGB-1,且与其它类似物无明显交叉反应 |
精密度 | 板内,板间变异系数均<10% |
回收率 | 80%-120% |
储存条件 | 2-8℃/-20℃ |
数据处理 |
-
Immunogenic Hybrid Nanovesicles of Liposomes and Tumor-Derived Nanovesicles for Cancer Immunochemotherapy
IF: 15.881 -
Transformable Nanoparticle‐Enabled Synergistic Elicitation and Promotion of Immunogenic Cell Death for Triple‐Negative Breast Cancer Immunotherapy
IF: 15.621Journal:ADVANCED FUNCTIONAL MATERIALS -
Liposome-mediated PD-L1 multivalent binding promotes the lysosomal degradation of PD-L1 for T cell-mediated antitumor immunity
IF: 15.304 -
Self-amplified ROS production from fatty acid oxidation enhanced tumor immunotherapy by atorvastatin/PD-L1 siRNA lipopeptide nanoplexes
IF: 15.304Journal:BIOMATERIALS -
Engineered macrophages as near-infrared light activated drug vectors for chemo-photodynamic therapy of primary and bone metastatic breast cancer
IF: 14.919 -
Mature dendritic cell-derived dendrosomes swallow oxaliplatin-loaded nanoparticles to boost immunogenic chemotherapy and tumor antigen-specific immunotherapy
IF: 14.593 -
Vanadyl nanocomplexes enhance photothermia-induced cancer immunotherapy to inhibit tumor metastasis and recurrence
IF: 12.479 -
Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy
IF: 12.479 -
Enhancing cancer chemo-immunotherapy by biomimetic nanogel with tumor targeting capacity and rapid drug-releasing in tumor microenvironment
IF: 11.614 -
Injectable Liquid Crystal Formation System for Reshaping Tumor Immunosuppressive Microenvironment to Boost Antitumor Immunity: Postoperative Chemoimmunotherapy
IF: 11.459